Evidence map›Paper›PMID 33756459›Full record

ReviewCerebrovascular diseases (Basel, Switzerland)2021

Stroke Care during the COVID-19 Pandemic: International Expert Panel Review.

Narayanaswamy Venketasubramanian, Craig Anderson, Hakan Ay, Selma Aybek, Waleed Brinjikji, Gabriel R de Freitas, Oscar H Del Brutto, Klaus Fassbender, Miki Fujimura, Larry B Goldstein and 33 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Cerebrovascular diseases (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Augmented reality for stroke rehabilitation during COVID-19.Journal of neuroengineering and rehabilitation · 2022
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. COVID-19 independently predicts poor outcomes in Acute Ischemic Stroke- Insights from a multicenter study from Pakistan and United Arab Emirates.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 20 countries.

Narayanaswamy VenketasubramanianRaffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore, drnvramani@gmail.com.
Craig AndersonThe George Institute for Global Health, Camperdown, Washington, Australia.
Hakan AyDepartments of Neurology and Radiology, Massachusetts General Hospital, Harvard School of Medicine, Boston, Massachusetts, USA.
Selma AybekDepartment of Neurology, University Hospital Inselspital, Bern University, Bern, Switzerland.
Waleed BrinjikjiDepartment of Radiology, Vascular Center, Mayo Clinic, Rochester, Minnesota, USA.
Gabriel R de FreitasInstituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil.
Oscar H Del BruttoSchool of Medicine, Universidad Espiritu Santo-Ecuador, Samborondón, Ecuador.
Klaus FassbenderDepartment of Neurology, Saarland University Medical Centre, Homburg, Germany.
Miki FujimuraDepartment of Neurosurgery, Kohnan Hospital, Sendai, Japan.
Larry B GoldsteinDepartment of Neurology, University of Kentucky, Lexington, Kentucky, USA.
Roman L HaberlDepartment of Neurology and Neurological Intensive Medicine, Munich Clinic gGmbH, Academic Teaching Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
Graeme J HankeyMedical School, The University of Western Australia, Perth, Washington, Australia.
Wolf-Dieter HeissMax-Planck-Institut für Neurologische Forschung, Cologne, Germany.
Isabel Lestro HenriquesDepartment of Neurosciences, Neurology Service, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal.
Carlos S KaseDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Jong S KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Masatoshi KogaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Yoshihiro KokuboDepartment of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Satoshi KurodaDepartment of Neurosurgery, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Kiwon LeeRutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
Tsong-Hai LeeDepartment of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
David S LiebeskindDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
Stephen MeairsDepartment of Neurology, Universitätsmedizin Mannheim, Mannheim, Germany.
Roman MedvedevResearch Center of Neurology, Moscow, Russian Federation.
Man Mohan MehndirattaDepartment of Neurology, Janakpuri Super Speciality Hospital, New Delhi, India.
Jay P MohrTananbaum Stroke Center, New York, New York, USA.
Masao NagayamaDepartment of Neurology, International University of Health and Welfare(IUHW), Graduate School of Medicine, Tokyo, Japan.
Leonardo PantoniDepartment of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Panagiotis PapanagiotouDepartment of Diagnostic and Interventional Neuroradiology, Klinikum Bremen-Mitte, Germany.
Guillermo ParrillaDepartment of Neurology, Interventional Neuroradiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Daniele PastoriDepartment of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Sarah T PendleburyDepartments of Internal Medicine and Geratology, John Radcliffe Hospital, Oxford, United Kingdom.
Luther Creed PettigrewDepartment of Neurology, University of Kentucky, Lexington, Kentucky, USA.
Pushpendra N RenjenDepartment of Neurosciences, Indraprastha Apollo Hospital, New Delhi, India.
Tatjana RundekDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Ulf SchminkeDepartment of Neurology, University Medicine, Greifswald, Germany.
Yukito ShinoharaTachikawa Hospital, Tokyo, Japan.
Wai Kwong TangDepartment of Psychiatry, Chinese University of Hong Kong, Shatin, Hong Kong, China.
Kazunori ToyodaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Katja E WartenbergDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Mohammad WasayDepartment of Medicine, Aga Khan University, Karachi, Pakistan.
Michael G HennericiDepartment of Neurology, Medical Faculty, Mannheim University of Heidelberg, Mannheim, Germany.
National Cerebral and Cardiovascular Center · JPUniversity of Kentucky · USAga Khan University · PKBLK Super Speciality Hospital · INChinese University of Hong Kong · HKEmory University · USHeidelberg University · DEHospital Universitario Virgen de la Arrixaca · ESIndraprastha Apollo Hospitals · INInternational University of Health and Welfare · JPJohn Radcliffe Hospital · GBLeipzig University · DELinkou Chang Gung Memorial Hospital · TWMassachusetts General Hospital · USMax Planck Institute for Metabolism Research · DEMayo Clinic · USMünchen Klinik · DENational and Kapodistrian University of Athens · GRRaffles Institution · SGResearch Center of Neurology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) has placed a tremendous strain on healthcare services. This study, prepared by a large international panel of stroke experts, assesses the rapidly growing research and personal experience with COVID-19 stroke and offers recommendations for stroke management in this challenging new setting: modifications needed for prehospital emergency rescue and hyperacute care; inpatient intensive or stroke units; posthospitalization rehabilitation; follow-up including at-risk family and community; and multispecialty departmental developments in the allied professions. SUMMARY: The severe acute respiratory syndrome coronavirus 2 uses spike proteins binding to tissue angiotensin-converting enzyme (ACE)-2 receptors, most often through the respiratory system by virus inhalation and thence to other susceptible organ systems, leading to COVID-19. Clinicians facing the many etiologies for stroke have been sobered by the unusual incidence of combined etiologies and presentations, prominent among them are vasculitis, cardiomyopathy, hypercoagulable state, and endothelial dysfunction. International standards of acute stroke management remain in force, but COVID-19 adds the burdens of personal protections for the patient, rescue, and hospital staff and for some even into the postdischarge phase. For pending COVID-19 determination and also for those shown to be COVID-19 affected, strict infection control is needed at all times to reduce spread of infection and to protect healthcare staff, using the wealth of well-described methods. For COVID-19 patients with stroke, thrombolysis and thrombectomy should be continued, and the usual early management of hypertension applies, save that recent work suggests continuing ACE inhibitors and ARBs. Prothrombotic states, some acute and severe, encourage prophylactic LMWH unless bleeding risk is high. COVID-19-related cardiomyopathy adds risk of cardioembolic stroke, where heparin or warfarin may be preferable, with experience accumulating with DOACs. As ever, arteritis can prove a difficult diagnosis, especially if not obvious on the acute angiogram done for clot extraction. This field is under rapid development and may generate management recommendations which are as yet unsettled, even undiscovered. Beyond the acute management phase, COVID-19-related stroke also forces rehabilitation services to use protective precautions. As with all stroke patients, health workers should be aware of symptoms of depression, anxiety, insomnia, and/or distress developing in their patients and caregivers. Postdischarge outpatient care currently includes continued secondary prevention measures. Although hoping a COVID-19 stroke patient can be considered cured of the virus, those concerned for contact safety can take comfort in the increasing use of telemedicine, which is itself a growing source of patient-physician contacts. Many online resources are available to patients and physicians. Like prior challenges, stroke care teams will also overcome this one. Key Messages: Evidence-based stroke management should continue to be provided throughout the patient care journey, while strict infection control measures are enforced.

Indexed as

Angiotensin Receptor AntagonistsCOVID-19Heparin, Low-Molecular-WeightHumansSARS-CoV-2Spike Glycoprotein, CoronavirusStrokeAngiotensin Receptor AntagonistsHeparin, Low-Molecular-WeightSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Coronavirus disease 2019ManagementReviewStroke

Identifiers

PMID33756459
PMCPMC8089455
OpenAlexW3138742332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.